SOPHIA GENETICS SA

Inside SOPHiA GENETICS insider sale: Kathleen Hibbs sells 6,250 shares amid market volatility, revealing potential signals for investors.

Insight on SOPHiA GENETICS: Valente Manuela’s $3.20 buy during a 15% rally signals insider confidence in the company’s undervalued stock and future growth.

Xu Zhenyu’s insider trades show disciplined buying amid SOPHiA GENETICS’ bullish trend—investors should watch leadership sales and future earnings for clear upside.

Insider sales by SOPHiA GENETICS’ top execs reveal disciplined liquidity plans, yet the firm’s strong earnings and AI‑driven growth keep it a compelling long‑term play.

Discover what SOPHiA GENETICS insider trading reveals about the company’s long‑term confidence and strategy.

Insider sales at SOPHiA GENETICS show disciplined liquidity planning, not a confidence dip—executive Jurgi’s July 7 trade confirms strong, rising fundamentals.

Insider selling spree at Sophia Genetics: CMO Menu Philippe sells 5,000 shares at $5.50 under Rule 10b5‑1, reflecting liquidity management amid a strategic shift to consumer‑SaaS products.

Insightful look at SOPHiA GENETICS insider trades: CFO sells shares for liquidity, not distress, as the company pushes its AI‑driven cloud platform.

Xu Zhenyu’s latest insider sell of 4,000 SOPHiA GENETICS shares reveals a cautious leadership stance, yet market impact remains minimal.

CEO Camblong Jurgi’s 8,500‑share sale before SOPHiA’s June 18 AGM signals a disciplined liquidity move, not a confidence dip, as the company gears up for a July 1 CEO transition that could unlock new upside for investors.